The nervous system type is called acute porphyria.

This is a non-specific finding that is not necessarily due to an acute porphyria.

It is recommended that patients with a history of acute porphyria, and even genetic carriers, wear an alert bracelet or other identification at all times.

Elevated porphobilinogen is indicative of an acute porphyria, and additional testing can be done to narrow down the specific type.

In 1889, he reported on a case of acute porphyria provoked by the newly introduced hypnotic drug sulfonmethane (sulfonal).

Bedside measurement of urine porphobilinogen is recommended as a screening test for patients suspected of having an acute porphyria.

In general, urine estimation of porphobilinogen (PBG) is the first step if acute porphyria is suspected.

Vlad III was also said to have suffered from acute porphyria, which may have started the notion that vampires were allergic to sunlight.

The effect of therapeutic drugs and other pharmacologic agents on activity of porphobilinogen deaminase, the enzyme that is deficient in intermittent acute porphyria.

For instance, the polyneuropathy of acute porphyria may be mistaken for Guillain-Barré syndrome, and porphyria testing is commonly recommended in those situations.

Hematin and heme arginate are the drugs of choice in acute porphyria, in the United States and the United Kingdom, respectively.

Patients with acute porphyria (AIP, HCP, VP) are at increased risk over their life for hepatocellular carcinoma (primary liver cancer) and may require monitoring.

Patients with a history of acute porphyria are recommended to wear an alert bracelet or other identification at all times in case they develop severe symptoms, a result of which may be that they cannot explain to healthcare professionals about their condition and the fact that some drugs are absolutely contraindicated.